Published: November 7, 2025 at 9:06 am
A listed University of Leeds spinout is in danger of going under this month.
Tissue Regenix Group appointed a new leadership team in October following the discovery of errors in previously reported revenues. Trading in its shares on London’s AIM market has also been suspended as it plans to restate its 2024 revenue figures.
After reviewing the company’s finances, Tissue Regenix Group said this morning they had uncovered a “substantial backlog of creditors and very limited cash balances”.
“Accordingly, the company has an urgent need to raise capital by the end of November. Without additional funding the Company will not be able to continue to trade,” it warned.
“The company is in discussion with its major shareholders and has clear indications of support to raise approximately £5m by way of a convertible loan note. Any fundraise will be subject to shareholder approval.”